WallStSmart
BDX

Becton Dickinson and Company

NYSE: BDX · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$149.04
+2.57% today

Updated 2026-04-30

Market cap
$41.34B
P/E ratio
23.74
P/S ratio
1.89x
EPS (TTM)
$6.12
Dividend yield
2.79%
52W range
$125 – $186
Volume
2.7M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Becton Dickinson and Company (BDX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$149.04
Consensus
$188.73
+26.63%
2030 Target
$803.45
+439.08%
DCF
$242.95
+25.66% MoS
12 analysts:
6 Buy6 Hold0 Sell

Management guidance

No specific multi-year revenue targets provided by management in available guidance. CEO commentary focuses on portfolio transformation following Biosciences spinoff/Waters merger completion (Feb 2026), positioning BD as pure-play medtech company. Guidance emphasizes high-margin software and automation growth, but no explicit revenue CAGR targets through 2030 disclosed.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$1,344.24
$24.3B Rev × 20x P/S
Base case (2030)
$803.45
$24.3B Rev × 12x P/S
Bear case (2030)
$540.79
$24.3B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$19.4B$20.2B$21.8B$19.5B$19.9B$21.0B$22.6B$24.3B
Revenue growth—4.2%8.2%-10.8%2.2%5.6%7.4%7.6%
EPS$12.22$13.16$2.91$12.57$13.63$15.20$16.95$18.85
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$648.94$664.39$695.30$741.65$803.45

Catalysts & risks

Growth catalysts
+ AI-enabled BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform European expansion driving high-margin recurring revenue
+ Surgiphor 1000mL antimicrobial irrigation system FDA clearance (Mar 2026) and international expansion in specialized surgical care
+ Post-spinoff pure-play medtech focus on medical delivery, interventional surgery, connected care with improved margin profile and capital allocation
+ Tuck-in M&A strategy in high-growth, high-margin segments to accelerate organic growth trajectory
Key risks
- Trade tariffs and geopolitical pressures impacting manufacturing costs and margins (recent FY26 profit outlook reduction)
- Execution risk on spinoff transition and Waters Corporation integration complexity
- Revenue headwinds in legacy diagnostic businesses pre-spinoff; FY2026 consensus shows -10.78% decline vs FY2025
- Competitive pressure from larger medtech players and smaller specialized innovators in surgical automation and connected care

Methodology

Becton Dickinson and Company's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 12 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.